Gut microorganisms as promising targets for the management of type 2 diabetes

Diabetologia

Volumn 58, Issue 10, 2015, Pages 2206-2217

  Delzenne, Nathalie M ^a   Cani, Patrice D ^a   Everard, Amandine ^a   Neyrinck, Audrey M ^a   Bindels, Laure B ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Diabetes; Glycaemia; Gut microbiota; Obesity; Prebiotic; Review

Indexed keywords

ARABINOXYLAN; FRUCTAN; METFORMIN; POLYPHENOL DERIVATIVE; PREBIOTIC AGENT; PROBIOTIC AGENT;

BARIATRIC SURGERY; DIABETIC PATIENT; DYSBIOSIS; FECES MICROFLORA; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HOST PATHOGEN INTERACTION; HUMAN; HYPERGLYCEMIA; INTESTINE CELL; INTESTINE FLORA; METABOLITE; METAGENOMICS; METHANOBREVIBACTER SMITHII; MICROBIOME; NIPPOSTRONGYLUS BRASILIENSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SACCHAROMYCES BOULARDII; SCHISTOSOMA MANSONI; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL TRACT; MICROBIOLOGY;

DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS;

EID: 84942191408     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3712-7     Document Type: Review

References (110)

1. Hoffmann C, Dollive S, Grunberg S et al (2013) Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One 8, e66019
2. Goodrich JK, Waters JL, Poole AC et al (2014) Human genetics shape the gut microbiome. Cell 159:789–799
3. Allin KH, Nielsen T, Pedersen O (2015) Mechanisms in endocrinology: gut microbiota in patients with type 2 diabetes mellitus. Eur J Endocrinol 172:R167–R177
4. Qin J, Li Y, Cai Z et al (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:55–60
5. Larsen N, Vogensen FK, van den Berg FW et al (2010) Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5, e9085
6. Karlsson FH, Tremaroli V, Nookaew I et al (2013) Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498:99–103
7. Sato J, Kanazawa A, Ikeda F et al (2014) Gut dysbiosis and detection of “live gut bacteria” in blood of Japanese patients with type 2 diabetes. Diabetes Care 37:2343–2350
8. Zhang X, Shen D, Fang Z et al (2013) Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One 8, e71108
9. Sepp E, Kolk H, Loivukene K, Mikelsaar M (2014) Higher blood glucose level associated with body mass index and gut microbiota in elderly people. Microb Ecol Health Dis. doi:10.3402/mehd.v25.22857
10. Le Chatelier E, Nielsen T, Qin J et al (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500:541–546
11. Vijay-Kumar M, Aitken JD, Carvalho FA et al (2010) Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328:228–231
12. Hameed I, Masoodi SR, Mir SA, Nabi M, Ghazanfar K, Ganai BA (2015) Type 2 diabetes mellitus: from a metabolic disorder to an inflammatory condition. World J Diabetes 6:598–612
13. Gregor MF, Hotamisligil GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29:415–445
14. Beutler B (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430:257–263
15. Cani PD, Amar J, Iglesias MA, et al (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 1761-1772
16. Cani PD, Bibiloni R, Knauf C et al (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57:1470–1481
17. Cani PD, Neyrinck AM, Fava F et al (2007) Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50:2374–2383
18. Sun L, Yu Z, Ye X et al (2010) A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care 33:1925–1932
19. Everard A, Geurts L, Caesar R et al (2014) Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status. Nat Commun 5:5648
20. Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD (2014) Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benefic Microbes 5:3–17
21. Denou E, Lolmede K, Garidou L et al (2015) Defective NOD2 peptidoglycan sensing promotes diet-induced inflammation, dysbiosis, and insulin resistance. EMBO Mol Med 9:259–274
22. Al-Daghri NM, Clerici M, Al-Attas O et al (2013) A nonsense polymorphism (R392X) in TLR5 protects from obesity but predisposes to diabetes. J Immunol 190:3716–3720
23. Reichardt N, Duncan SH, Young P et al (2014) Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. ISME J 8:1323–1335
24. Reimann F, Tolhurst G, Gribble FM (2012) G-protein-coupled receptors in intestinal chemosensation. Cell Metab 15:421–431
25. Tolhurst G, Heffron H, Lam YS et al (2012) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61:364–371
26. Plaisancie P, Dumoulin V, Chayvialle JA, Cuber JC (1995) Luminal glucagon-like peptide-1(7-36) amide-releasing factors in the isolated vascularly perfused rat colon. J Endocrinol 145:521–526
27. Lin HV, Frassetto A, Kowalik EJ Jr et al (2012) Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One 7, e35240
28. Frost G, Sleeth ML, Sahuri-Arisoylu M et al (2014) The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun 5:3611
29. Bindels LB, Dewulf EM, Delzenne NM (2013) GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol Sci 34:226–232
30. Everard A, Cani PD (2014) Gut microbiota and GLP-1. Rev Endocr Metab Disord 15:189–196
31. De Vadder F, Kovatcheva-Datchary P, Goncalves D et al (2014) Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156:84–96
32. Yokoyama MT, Carlson JR (1979) Microbial metabolites of tryptophan in the intestinal tract with special reference to skatole. Am J Clin Nutr 32:173–178
33. DeMoss RD, Moser K (1969) Tryptophanase in diverse bacterial species. J Bacteriol 98:167–171
34. Chimerel C, Emery E, Summers DK, Keyser U, Gribble FM, Reimann F (2014) Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep 9:1202–1208
35. Leclercq S, Matamoros S, Cani PD et al (2014) Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci U S A 111:E4485–E4493
36. Cani PD, Possemiers S, Van de WT et al (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58:1091–1103
37. Thomas C, Gioiello A, Noriega L et al (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10:167–177
38. Hwang I, Park YJ, Kim YR et al (2015) Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon-like peptide 1 in diet-induced obesity. FASEB J 29:2397–2411
39. Claus SP, Tsang TM, Wang Y et al (2008) Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol 4:219
40. Sayin SI, Wahlstrom A, Felin J et al (2013) Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17:225–235
41. Prawitt J, Caron S, Staels B (2011) Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep 11:160–166
42. Bala V, Rajagopal S, Kumar DP et al (2014) Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC-ε pathway and modulated by endogenous H2S. Front Physiol 5:420
43. Li F, Jiang C, Krausz KW et al (2013) Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 4:2384
44. Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A (2014) Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr–Fgf15 axis in mice. Cell Rep 7:12–18
45. Joyce SA, MacSharry J, Casey PG et al (2014) Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci U S A 111:7421–7426
46. Martoni CJ, Labbe A, Ganopolsky JG, Prakash S, Jones ML (2015) Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. reuteri NCIMB 30242. Gut Microbes 6:57–65
47. Rena G, Pearson ER, Sakamoto K (2013) Molecular mechanism of action of metformin: old or new insights? Diabetologia 56:1898–1906
48. Bonora E, Cigolini M, Bosello O et al (1984) Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects. Curr Med Res Opin 9:47–51
49. Shin NR, Lee JC, Lee HY et al (2014) An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63:727–735
50. Everard A, Belzer C, Geurts L et al (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110:9066–9071
51. Lee H, Ko G (2014) Effect of metformin on metabolic improvement and gut microbiota. Appl Environ Microbiol 80:5935–5943
52. Su B, Liu H, Li J et al (2014) Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. J Diabetes. doi:10.1111/1753-0407.12232
53. Reimer RA, Grover GJ, Koetzner L et al (2012) Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats. J Nutr 142:1812–1820
54. Reimer RA, Grover GJ, Koetzner L, Gahler RJ, Lyon MR, Wood S (2014) Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats. J Endocrinol 220:361–373
55. Schauer PR, Kashyap SR, Wolski K et al (2012) Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366:1567–1576
56. Liou AP, Paziuk M, Luevano JM Jr, Machineni S, Turnbaugh PJ, Kaplan LM (2013) Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 5:178ra41
57. Aron-Wisnewsky J, Dore J, Clement K (2012) The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol Hepatol 9:590–598
58. Ryan KK, Tremaroli V, Clemmensen C et al (2014) FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509:183–188
59. Vrieze A, van Nood E, Holleman F et al (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143:913–916
60. Hill C, Guarner F, Reid G et al (2014) Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11:506–514
61. Bukowska H, Pieczul-Mroz J, Jastrzebska M, Chelstowski K, Naruszewicz M (1998) Decrease in fibrinogen and LDL-cholesterol levels upon supplementation of diet with Lactobacillus plantarum in subjects with moderately elevated cholesterol. Atherosclerosis 137:437–438
62. Andreasen AS, Larsen N, Pedersen-Skovsgaard T et al (2010) Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr 104:1831–1838
63. Ogawa A, Kadooka Y, Kato K, Shirouchi B, Sato M (2014) Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic subjects. Lipids Health Dis 13:36
64. Miquel S, Martin R, Bridonneau C et al (2014) Ecology and metabolism of the beneficial intestinal commensal bacterium Faecalibacterium prausnitzii. Gut Microbes 5:146–151
65. Mukherjee PK, Sendid B, Hoarau G, Colombel JF, Poulain D, Ghannoum MA (2015) Mycobiota in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 12:77–87
66. Everard A, Matamoros S, Geurts L, Delzenne NM, Cani PD (2014) Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. MBio 5:e01011–e01014
67. Samuel BS, Gordon JI (2006) A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proc Natl Acad Sci U S A 103:10011–10016
68. Zhang H, DiBaise JK, Zuccolo A et al (2009) Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 106:2365–2370
69. Basseri RJ, Basseri B, Pimentel M et al (2012) Intestinal methane production in obese individuals is associated with a higher body mass index. Gastroenterol Hepatol (N Y) 8:22–28
70. Fernandes J, Wang A, Su W et al (2013) Age, dietary fiber, breath methane, and fecal short chain fatty acids are interrelated in Archaea-positive humans. J Nutr 143:1269–1275
71. Wu D, Molofsky AB, Liang HE et al (2011) Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332:243–247
72. Wang Y, Holmes E, Nicholson JK et al (2004) Metabonomic investigations in mice infected with Schistosoma mansoni: an approach for biomarker identification. Proc Natl Acad Sci U S A 101:12676–12681
73. Walk ST, Blum AM, Ewing SA, Weinstock JV, Young VB (2010) Alteration of the murine gut microbiota during infection with the parasitic helminth Heligmosomoides polygyrus. Inflamm Bowel Dis 16:1841–1849
74. Reynolds LA, Smith KA, Filbey KJ et al (2014) Commensal-pathogen interactions in the intestinal tract: lactobacilli promote infection with, and are promoted by, helminth parasites. Gut Microbes 5:522–532
75. Thondre PS (2013) Food-based ingredients to modulate blood glucose. Adv Food Nutr Res 70:181–227
76. Bindels LB, Delzenne NM, Cani PD, Walter J (2015) Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol 12:303–310
77. Cani PD, Dewever C, Delzenne NM (2004) Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. Br J Nutr 92:521–526
78. Delzenne NM, Cani PD, Daubioul C, Neyrinck AM (2005) Impact of inulin and oligofructose on gastrointestinal peptides. Br J Nutr 93(Suppl 1):S157–S161
79. Cani PD, Daubioul CA, Reusens B, Remacle C, Catillon G, Delzenne NM (2005) Involvement of endogenous glucagon-like peptide-1(7-36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats. J Endocrinol 185:457–465
80. Cani PD, Neyrinck AM, Maton N, Delzenne NM (2005) Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like peptide-1. Obes Res 13:1000–1007
81. Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM, Burcelin R (2006) Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes 55:1484–1490
82. Bonsu NK, Johnson CS, McLeod KM (2011) Can dietary fructans lower serum glucose? J Diabetes 3:58–66
83. Cani PD, Lecourt E, Dewulf EM et al (2009) Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 90:1236–1243
84. Tripkovic L, Muirhead NC, Hart KH, Frost GS, Lodge JK (2014) The effects of a diet rich in inulin or wheat fibre on markers of cardiovascular disease in overweight male subjects. J Hum Nutr Diet. doi:10.1111/jhn.12251
85. Dehghan P, Pourghassem Gargari B, Asghari Jafar-abadi M (2014) Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial. Nutrition 30:418–423
86. Dewulf EM, Cani PD, Claus SP et al (2013) Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 62:1112–1121
87. Neyrinck AM, Delzenne NM (2010) Potential interest of gut microbial changes induced by non-digestible carbohydrates of wheat in the management of obesity and related disorders. Curr Opin Clin Nutr Metab Care 13:722–728
88. Andersson AA, Andersson R, Piironen V et al (2013) Contents of dietary fibre components and their relation to associated bioactive components in whole grain wheat samples from the HEALTHGRAIN diversity screen. Food Chem 136:1243–1248
89. Grootaert C, Van den Abbeele P, Marzorati M et al (2009) Comparison of prebiotic effects of arabinoxylan oligosaccharides and inulin in a simulator of the human intestinal microbial ecosystem. FEMS Microbiol Ecol 69:231–242
90. Vardakou M, Palop CN, Christakopoulos P, Faulds CB, Gasson MA, Narbad A (2008) Evaluation of the prebiotic properties of wheat arabinoxylan fractions and induction of hydrolase activity in gut microflora. Int J Food Microbiol 123:166–170
91. Hughes SA, Shewry PR, Li L, Gibson GR, Sanz ML, Rastall RA (2007) In vitro fermentation by human fecal microflora of wheat arabinoxylans. J Agric Food Chem 55:4589–4595
92. Neyrinck AM, Van Hee VF, Piront N et al (2012) Wheat-derived arabinoxylan oligosaccharides with prebiotic effect increase satietogenic gut peptides and reduce metabolic endotoxemia in diet-induced obese mice. Nutr Diabetes 2, e28
93. Neyrinck AM, Possemiers S, Druart C et al (2011) Prebiotic effects of wheat arabinoxylan related to the increase in bifidobacteria, Roseburia and Bacteroides/Prevotella in diet-induced obese mice. PLoS One 6, e20944
94. Neyrinck AM, Van Hee VF, Bindels LB, De BF, Cani PD, Delzenne NM (2013) Polyphenol-rich extract of pomegranate peel alleviates tissue inflammation and hypercholesterolaemia in high-fat diet-induced obese mice: potential implication of the gut microbiota. Br J Nutr 109:802–809
95. Dao TM, Waget A, Klopp P et al (2011) Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS One 6, e20700
96. Axling U, Olsson C, Xu J et al (2012) Green tea powder and Lactobacillus plantarum affect gut microbiota, lipid metabolism and inflammation in high-fat fed C57BL/6J mice. Nutr Metab (Lond) 9:105
97. Anhe FF, Roy D, Pilon G et al (2014) A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut 64:872–883
98. Xu J, Lian F, Zhao L et al (2015) Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. ISME J 9:552–562
99. Suez J, Korem T, Zeevi D et al (2014) Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 514:181–186
100. Feehley T, Nagler CR (2014) Health: the weighty costs of non-caloric sweeteners. Nature 514:176–177
101. Vogel B, Gallaher DD, Bunzel M (2012) Influence of cross-linked arabinoxylans on the postprandial blood glucose response in rats. J Agric Food Chem 60:3847–3852
102. Christensen KL, Hedemann MS, Laerke HN et al (2013) Concentrated arabinoxylan but not concentrated beta-glucan in wheat bread has similar effects on postprandial insulin as whole-grain rye in porto-arterial catheterized pigs. J Agric Food Chem 61:7760–7768
103. Hartvigsen ML, Jeppesen PB, Laerke HN, Njabe EN, Knudsen KE, Hermansen K (2013) Concentrated arabinoxylan in wheat bread has beneficial effects as rye breads on glucose and changes in gene expressions in insulin-sensitive tissues of Zucker diabetic fatty (ZDF) rats. J Agric Food Chem 61:5054–5063
104. Lu ZX, Gibson PR, Muir JG, Fielding M, O’Dea K (2000) Arabinoxylan fiber from a by-product of wheat flour processing behaves physiologically like a soluble, fermentable fiber in the large bowel of rats. J Nutr 130:1984–1990
105. Lu ZX, Walker KZ, Muir JG, O'Dea K (2004) Arabinoxylan fibre improves metabolic control in people with type II diabetes. Eur J Clin Nutr 58:621–628
106. Garcia AL, Otto B, Reich SC et al (2007) Arabinoxylan consumption decreases postprandial serum glucose, serum insulin and plasma total ghrelin response in subjects with impaired glucose tolerance. Eur J Clin Nutr 61:334–341
107. Garcia AL, Steiniger J, Reich SC et al (2006) Arabinoxylan fibre consumption improved glucose metabolism, but did not affect serum adipokines in subjects with impaired glucose tolerance. Horm Metab Res 38:761–766
108. Mohlig M, Koebnick C, Weickert MO et al (2005) Arabinoxylan-enriched meal increases serum ghrelin levels in healthy humans. Horm Metab Res 37:303–308
109. Maki KC, Gibson GR, Dickmann RS et al (2012) Digestive and physiologic effects of a wheat bran extract, arabino-xylan-oligosaccharide, in breakfast cereal. Nutrition 28:1115–1121
110. Hartvigsen ML, Laerke HN, Overgaard A, Holst JJ, Bach Knudsen KE, Hermansen K (2014) Postprandial effects of test meals including concentrated arabinoxylan and whole grain rye in subjects with the metabolic syndrome: a randomised study. Eur J Clin Nutr 68:567–574